Serum Biomarkers in Parkinson's Disease at Different Stages
Study Details
Study Description
Brief Summary
-
Determine clinical characteristics of parkinsonian patients in various stages of disease;
-
Measure peripheral neurodegeneration, synaptic, and inflammation biomarkers in a population of parkinsonian patients at various stages of disease.
-
Measure vesicular neurodegeneration, synaptic and inflammation biomarkers
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Biomarkers
|
Procedure: blood sample
blood sample
|
Outcome Measures
Primary Outcome Measures
- Determine clinical characteristics of parkinsonian patients in various stages of disease [3 years]
Determine clinical characteristics of parkinsonian patients in various stages of disease by means of MDS-UPDRS score changes.
- Determine clinical characteristics of parkinsonian patients in various stages of disease [3 years]
Determine clinical characteristics of parkinsonian patients in various stages of disease by means of NMS score changes.
- Determine biooogical characteristics of parkinsonian patients in various stages of disease [3 years]
dosage of serum IL-1b, IL6, IL-5, IL-4, IL17, TNFa, IFNg, IL10, total-alpha-synuclein, NfL, BDNF (ng/ml for all)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients diagnosed with idiopathic PD according to Movement Disorders Society (MDS) criteria;
-
Age: 18-80 years;
-
Signature of informed consent to participate in this study
Exclusion criteria.
-
Women pregnant
-
Inflammatory or autoimmune diseases
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Flavia Torlizzi | Roma | Italy | 00168 |
Sponsors and Collaborators
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 4687